Lista de obras -

A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study

artículo científico publicado en 2016

A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study

artículo científico publicado en 2013

A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors

scientific article published on 22 January 2020

A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas

artículo científico publicado en 2010

A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer

artículo científico publicado en 2005

A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium

artículo científico publicado en 2011

A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma ⬇️

artículo científico publicado el 28 de julio de 2011

An LC/ESI-MS/MS method to quantify the PI3K inhibitor GDC-0084 in human plasma and cerebrospinal fluid: Validation and clinical application

scientific article published on 21 October 2019

An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.

artículo científico publicado en 2011

Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood

artículo científico publicado en 2009

CNS penetration of the CDK4/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors

scientific article published on 11 May 2019

Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma

artículo científico publicado en 2010

Clinical pharmacology in the adolescent oncology patient

artículo científico publicado en 2010

Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia.

artículo científico publicado en 2010

Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss

artículo científico publicado en 2015

Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections

artículo científico publicado en 2014

Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patients.

artículo científico publicado en 2017

Determination of dopamine, serotonin, and their metabolites in pediatric cerebrospinal fluid by isocratic high performance liquid chromatography coupled with electrochemical detection

artículo científico publicado en 2010

Determining success rates of the current pharmacokinetically guided dosing approach of topotecan in pediatric oncology patients

scientific article published on 11 December 2018

Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier

scientific journal article

Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid tumors ⬇️

artículo científico publicado el 20 de abril de 2011

Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib

artículo científico publicado en 2010

Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma

artículo científico publicado en 2014

Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients

artículo científico publicado en 2006

Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma.

artículo científico publicado en 2016

Immunohistochemical detection of multidrug-resistant protein expression in retinoblastoma treated by primary enucleation

artículo científico publicado en 2006

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

artículo científico publicado en 2009

LGG-02. A PHASE II PROSPECTIVE TRIAL OF SELUMETINIB IN CHILDREN WITH RECURRENT/PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (PLGG) WITH A FOCUS UPON OPTIC PATHWAY/HYPOTHALAMIC TUMORS AND VISUAL ACUITY OUTCOMES: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) ST

MBCL-44. THE MOLECULAR AND CLINICAL LANDSCAPE OF INFANT MEDULLOBLASTOMA (iMB): RESULTS AND MOLECULAR ANALYSIS FROM A PROSPECTIVE, MULTICENTER PHASE II TRIAL (SJYC07)

MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport ⬇️

artículo científico publicado el 1 de julio de 2011

Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells

artículo científico publicado en 2014

Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group.

artículo científico publicado en 2013

Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma

artículo científico publicado en 2016

Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)

artículo científico publicado en 2021

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report

artículo científico publicado en 2010

Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma

artículo científico publicado en 2014

Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours

scientific article published on 08 January 2020

Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.

artículo científico publicado en 2012

Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors

artículo científico publicado en 2009

Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study

artículo científico publicado en 2009

Phase I Trial of Lenalidomide in Pediatric Patients With Recurrent, Refractory, or Progressive Primary CNS Tumors: Pediatric Brain Tumor Consortium Study PBTC-018 ⬇️

artículo científico publicado el 13 de diciembre de 2010

Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.

artículo científico publicado en 2012

Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors

artículo científico publicado en 2004

Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study

artículo científico publicado en 2014

Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors

artículo científico publicado en 2014

Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma

artículo científico publicado en 2010

Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study

artículo científico publicado en 2011

Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study

artículo científico publicado en 2010

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study

artículo científico publicado en 2009

Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report

artículo científico publicado en 2007

Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study

artículo científico publicado en 2015

Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study

artículo científico publicado en 2010

Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing

artículo científico publicado en 2015

Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing

artículo científico publicado en 2014

Reducing irinotecan-associated diarrhea in children

artículo científico publicado en 2008

Resumption of high‐dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients ⬇️

artículo científico publicado el 17 de enero de 2012

Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial

scientific article published on 16 May 2018

Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation ⬇️

artículo científico publicado el 18 de noviembre de 2010

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial

scientific article published on 28 May 2019

Stability of cyclophosphamide in extemporaneous oral suspensions

artículo científico publicado en 2010

Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity ⬇️

artículo científico publicado el 19 de abril de 2012

Topotecan disposition in an anephric child

artículo científico publicado en 2004

Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study

artículo científico publicado en 2007

Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors

artículo científico publicado en 2009

Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma

artículo científico publicado en 2008

Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.

artículo científico publicado en 2015

Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.

artículo científico publicado en 2010

Lista de obras de

A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study

A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study

A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors

A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas

A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer

A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium

A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma ⬇️

An LC/ESI-MS/MS method to quantify the PI3K inhibitor GDC-0084 in human plasma and cerebrospinal fluid: Validation and clinical application

An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.

Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood

CNS penetration of the CDK4/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors

Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma

Clinical pharmacology in the adolescent oncology patient

Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia.

Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss

Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections

Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patients.

Determination of dopamine, serotonin, and their metabolites in pediatric cerebrospinal fluid by isocratic high performance liquid chromatography coupled with electrochemical detection

Determining success rates of the current pharmacokinetically guided dosing approach of topotecan in pediatric oncology patients

Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier

Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid tumors ⬇️

Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib

Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma

Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients

Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma.

Immunohistochemical detection of multidrug-resistant protein expression in retinoblastoma treated by primary enucleation

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

LGG-02. A PHASE II PROSPECTIVE TRIAL OF SELUMETINIB IN CHILDREN WITH RECURRENT/PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (PLGG) WITH A FOCUS UPON OPTIC PATHWAY/HYPOTHALAMIC TUMORS AND VISUAL ACUITY OUTCOMES: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) ST

MBCL-44. THE MOLECULAR AND CLINICAL LANDSCAPE OF INFANT MEDULLOBLASTOMA (iMB): RESULTS AND MOLECULAR ANALYSIS FROM A PROSPECTIVE, MULTICENTER PHASE II TRIAL (SJYC07)

MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport ⬇️

Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells

Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group.

Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma

Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report

Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma

Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours

Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.

Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors

Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study

Phase I Trial of Lenalidomide in Pediatric Patients With Recurrent, Refractory, or Progressive Primary CNS Tumors: Pediatric Brain Tumor Consortium Study PBTC-018 ⬇️

Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.

Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors

Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study

Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors

Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma

Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study

Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study

Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report

Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study

Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study

Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing

Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing

Reducing irinotecan-associated diarrhea in children

Resumption of high‐dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients ⬇️

Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial

Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation ⬇️

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial

Stability of cyclophosphamide in extemporaneous oral suspensions

Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity ⬇️

Topotecan disposition in an anephric child

Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study

Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors

Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma

Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.

Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.